Beyond clinical endpoints: Rethinking ALS drug development through disease biology Read more 

With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’ Read more 

Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition Read more 

Max Eldridge

Max has more than ten years in Life Sciences recruitment, He collaborates with executives to foster growth in Pharma, Biotech, CRO, TechBio, and Medical Device sectors​

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2026 | Hlx Life Sciences

Go to Top